Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Xponance Inc.

Xponance Inc. raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 76,761 shares of the medical research company’s stock after acquiring an additional 3,487 shares during the quarter. Xponance Inc.’s holdings in Thermo Fisher Scientific were worth $40,744,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in TMO. Bornite Capital Management LP grew its stake in shares of Thermo Fisher Scientific by 50.0% during the 1st quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock worth $17,719,000 after purchasing an additional 10,000 shares during the period. Fairfield Bush & CO. grew its stake in Thermo Fisher Scientific by 1.2% in the 1st quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock valued at $1,729,000 after acquiring an additional 36 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in Thermo Fisher Scientific by 563.5% in the 1st quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock valued at $11,721,000 after acquiring an additional 16,853 shares during the last quarter. Covestor Ltd grew its stake in Thermo Fisher Scientific by 60.5% in the 1st quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock valued at $190,000 after acquiring an additional 121 shares during the last quarter. Finally, Merit Financial Group LLC grew its stake in Thermo Fisher Scientific by 3.6% in the 1st quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock valued at $395,000 after acquiring an additional 23 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

TMO has been the topic of a number of recent research reports. HSBC upped their target price on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Royal Bank of Canada increased their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Barclays lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Raymond James lifted their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Stock Down 1.0 %

Shares of NYSE:TMO traded down $5.73 during midday trading on Thursday, reaching $541.52. The company had a trading volume of 2,075,755 shares, compared to its average volume of 1,542,233. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The stock’s fifty day moving average price is $571.57 and its 200-day moving average price is $527.01. The stock has a market capitalization of $206.70 billion, a P/E ratio of 34.94, a PEG ratio of 2.33 and a beta of 0.80. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the previous year, the firm earned $5.40 earnings per share. The firm’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.